Brought to you by 
Knight Therapeutics raises Cdn$230mm in bought deal financing
02 Jun 2016
Executive Summary
Specialty pharma company Knight Therapeutics Inc. raised Cdn$230mm ($179mm) in a bought deal financing of 28.75mm common shares (including full exercise of the over-allotment option of 3.75mm shares) at Cdn$8 ($6.24). The deal was done by an underwriting syndicate led by GMP Securities L.P.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- FOPO
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Knight Therapeutics raises Cdn$230mm in bought deal financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice